<DOC>
	<DOCNO>NCT00002810</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth plasma cell , either kill cell stop divide . Having peripheral stem cell transplant replace blood-forming cell destroy chemotherapy , allow high dos chemotherapy give plasma cell kill . By reduce number plasma cell , disease may progress slowly . PURPOSE : This phase II trial study well give high-dose melphalan together peripheral stem cell transplant work treat patient primary amyloidosis amyloidosis associate multiple myeloma .</brief_summary>
	<brief_title>High-Dose Melphalan Followed Peripheral Stem Cell Transplant Treating Patients With Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : - Assess overall progression-free survival follow high-dose melphalan autologous peripheral blood stem cell transplantation patient primary amyloidosis . - Evaluate toxic effect associate treatment regimen . - Evaluate function involve organ , especially heart , lung , nervous system , treatment regimen . OUTLINE : Peripheral blood stem cell ( PBSC ) mobilize granulocyte colony-stimulating factor ( G-CSF ) 5 day collect leukapheresis . Patients receive high-dose melphalan 2 consecutive day , follow 1 day rest , PBSC transplantation . G-CSF give 1 day transplantation neutrophil count great 1,500 3 consecutive day . Patients follow 100 day 1 year post-transplant . PROJECTED ACCRUAL : A small number patient expect accrued 5-10 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Primary amyloidosis diagnose appropriate amyloid stain electromicroscopy abdominal fat , bone marrow , target tissue Pathology review Temple University Amyloidosis secondary stage multiple myeloma allow provide plasma cell concentration bone marrow le 15 % No amyloidosis secondary rheumatoid arthritis chronic infection No familial amyloidosis PATIENT CHARACTERISTICS : Age : 16 65 Performance status : Karnofsky 80100 % Hematopoietic : Not specify Hepatic : Liver function test less twice normal No active liver disease Renal : Creatinine clearance great 50 mL/min Nephrotic syndrome allow Cardiovascular : Cardiac evaluation require patient leave ventricular ejection fraction le 45 % echocardiogram MUGA No poorly control hypertension Pulmonary : FEV_1 DLCO great 50 % predict , pulmonary evaluation require No chronic obstructive pulmonary disease Other : No history serious coagulopathy , hemorrhage , bleed No active infection No serious comorbid disease ( e.g. , poorly control diabetes ) No pregnant woman Adequate contraception require fertile woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : More 12 monthly cycle prior alkylating agent chemotherapy discourage Endocrine therapy : Corticosteroids discontinue least 6 week prior transplantation Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>